Stevens–Johnson Syndrome and Herpes Simplex Type 1 Infection during Adalimumab Therapy for Crohn’s Disease by Jenny Roselli, Tommaso Innocenti, Erica Nicola Lynch, Laura Parisio, Pasquale Apolito, Tommaso Mello, Giuseppe Macrì, Monica Milla, Maria Rosa Biagini, Mirko Tarocchi, Stefano Milani, Andrea Galli

“…SJS is described during herpes simplex virus type 1 (HSV1) infection and, rarely, even during adalimumab therapy. We report the case of a patient with Crohn’s disease who developed SJS during an HSV1 infection and a contemporaneous anti-TNFα therapy with adalimumab. …”
Get full text

Adalimumab Treatment in Biologically Naïve Crohn’s Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement by Tsutomu Mizoshita, Satoshi Tanida, Hironobu Tsukamoto, Keiji Ozeki, Takahito Katano, Hirotaka Nishiwaki, Masahide Ebi, Yoshinori Mori, Eiji Kubota, Hiromi Kataoka, Takeshi Kamiya, Takashi Joh

“…Background. Adalimumab (ADA) is effective for patients with Crohn’s disease (CD). …”
Get full text

Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension by Gerd R Burmester, Mark C Genovese, Vibeke Strand, Gregory St John, Andrea Rubbert-Roth, Howard Amital, Tatiana Raskina, Antonio Gómez-Centeno, Claudia Pena-Rossi, Leon Gervitz, Karthinathan Thangavelu, Susan Boklage

“…Safety (March 2017 cut-off) and efficacy, including patient-reported outcomes, were evaluated.Results In the double-blind phase, patients receiving sarilumab or adalimumab monotherapy showed meaningful improvements in disease activity; sarilumab was superior to adalimumab for improving signs, symptoms and physical function. …”
Get full text

Involvement of HLADQA1*05 in Patients with Inflammatory Bowel Disease Treated with Anti-TNF Drugs by Anna Pau, Ilaria Galliano, Elisa Barnini, Maddalena Dini, Antonio Pizzol, Alice Ponte, Stefano Gambarino, Pier Luigi Calvo, Massimiliano Bergallo

Subjects: Get full text

Case report: dysgeusia, strawberry tongue, and psoriatic eruptions after combination treatment with adalimumab, sulfasalazine, and etoricoxib for ankylosing spondylitis by Binglin Cui, Jing Lin, Yuanchun Huang, Huachen Zhu, Huachen Zhu, Huachen Zhu, Jinbo Zou, Jiesheng Qin, Hui Pan, Hui Pan, Jian Chen

Subjects: Get full text

Successful treatment of pyoderma gangrenosum complicated by JAK2V617F mutation-positive myelofibrosis with adalimumab and systemic steroid by Kyohei Shibuta, Koremasa Hayama, Katsuhiro Miura, Hideki Fujita

Subjects: Get full text

Anti-TROVE2 Antibody Determined by Immune-Related Array May Serve as a Predictive Marker for Adalimumab Immunogenicity and Effectiveness in RA by Po-Ku Chen, Joung-Liang Lan, Yi-Ming Chen, Hsin-Hua Chen, Shih-Hsin Chang, Chia-Min Chung, Nurul H. Rutt, Ti-Myen Tan, Raja Nurashirin Raja Mamat, Nur Diana Anuar, Jonathan M. Blackburn, Der-Yuan Chen

“…With a treat-to-target goal, we aimed to identify biomarkers for predicting ADAb development and therapeutic response in adalimumab-treated patients. Three independent cohorts were enrolled. …”
Get full text

Rheumatoid arthritis associated cytokines and therapeutics modulate immune checkpoint receptor expression on T cells by Dana Emerson, Eve Merriman, Pia P. Yachi

Subjects: Get full text

Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial by Selma Atalay, Sophie E. Berends, Hans M. M. Groenewoud, Ron A. A. Mathot, David M. Njoo, Johannes M. Mommers, Paul M. Ossenkoppele, Marjolein I. A. Koetsier, Maartje A. Berends, Annick de Vries, Peter C. M. van de Kerkhof, Alfons A. den Broeder, Elke M. G. J. de Jong, Juul M. P. A. van den Reek

Subjects: Get full text

Anti-TNF-Alpha-Adalimumab Therapy Had Time Lag of Improvement in Synovial Hypertrophy Compared to Rapid Response in Power Doppler Synovial Vascularity by Ying-Chou Chen, Chi-Hua Ko, Jia-Feng Chen, Chung-Yuan Hsu, Wen-Chan Chiu, Tien-Tsai Cheng

“…The 71 patients who received adalimumab therapy had significantly decreased DAS28, ESR, and CRP. …”
Get full text

Adalimumab (TNFα Inhibitor) Therapy Exacerbates IgA Glomerulonephritis Acute Renal Injury and Induces Lupus Autoantibodies in a Psoriasis Patient by S. S. Wei, R. Sinniah

“…Renal biopsy is the key diagnostic tool in patients presenting with adalimumab induced nephritis and renal failure. He made a remarkable recovery after adalimumab cessation and steroid treatment. …”
Get full text

Deficiency of Interleukin-1 Receptor Antagonist: A Case with Late Onset Severe Inflammatory Arthritis, Nail Psoriasis with Onychomycosis and Well Responsive to Adalimumab Therapy by Necil Kutukculer, Anne Puel, Sanem Eren Akarcan, Kunihiko Moriya, Neslihan Edeer Karaca, Melanie Migaud, Jean-Laurent Casanova, Guzide Aksu

“…The case responded well and fully recovered after treatment with adalimumab, but not with canakinumab. The DIRA disease can lead to death from multiple organ failures and if recognized early, the treatment with replacement of the deficient protein with biologic agents induces rapid and complete remission. …”
Get full text

Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study by Bruno Fautrel, Yoram Bouhnik, Carine Salliot, Franck Carbonnel, Mathurin Fumery, Christophe Bernardeau, Yves Maugars, Mathurin Flamant, Fabienne Coury, Ben Braithwaite, Salima Hateb, Janet Addison, the PERFUSE investigators

“…Abstract Background There is a need for published data on real-world use of SB5, an adalimumab (ADL) biosimilar approved in Europe in 2017, on the basis of evidence from pre-clinical and analytic data as well as phase I and III clinical studies demonstrating equivalent efficacy and comparable pharmacokinetics, safety and immunogenicity profiles as the reference ADL. …”
Get full text

Therapeutic drug monitoring and neutralizing anti-drug antibody detection to optimize TNF-alpha inhibitor treatment for uveitis by Howard C. Chen, Jenny Shunyakova, Amit K. Reddy, Srujay Pandiri, Lynn Hassman

Subjects: Get full text

Inflammatory Bowel Diseases in Children: Modern Achievements in Diagnostics and Therapy by A. I. Khavkin, A. V. Nalyotov, N. A. Marchenko

Subjects: Get full text

Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials by Jing Yang, Zongming Wang, Xilin Zhang

“…Meanwhile, there was no statistically significant association of infections and serious infections compared with the placebo or adalimumab group. The guselkumab was more effective and had the similar tolerance. …”
Get full text

Use of biologic response modifiers for the management of ocular inflammatory conditions by Erick Rivera-Grana, Jay Siak, James T Rosenbaum

“…We review and discuss, (1) a 60-year-old male with granulomatosis with polyangiitis and bilateral anterior scleritis who required rituximab; (2) a 25-year-old male with refractory, idiopathic, bilateral chronic panuveitis and retinal vasculitis, which was controlled with adalimumab after treatment failure with oral and topical corticosteroids, cyclosporine, and methotrexate; and (3) a 44-year-old female with unilateral blindness and juvenile psoriatic arthritis-related intermediate uveitis, who required adalimumab to control her complication of persistent macular edema. …”
Get full text

Systematic review and bayesian network meta-analysis: comparative efficacy and safety of six commonly used biologic therapies for moderate-to-severe Crohn’s disease by Haohang Su, Haohang Su, Shengwei Xiao, Zhiqing Liang, Zhiqing Liang, Tianrong Xun, Jinfang Zhang, Jinfang Zhang, Xixiao Yang, Xixiao Yang

“…Risankizumab potentially has the lowest safety risk worth exploring in induction therapy. Adalimumab and the 10 mg/kg regimen of Infliximab have maintenance efficacy benefits for responders to induction therapy.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?…”
Get full text

Liver Injury Secondary to Anti-TNF-Alpha Therapy in Inflammatory Bowel Disease: A Case Series and Review of the Literature by Ravish Parekh, Nirmal Kaur

“…One patient was successfully transitioned from infliximab to adalimumab without relapse of either IBD or liver injury. …”
Get full text

Three Cases of Previous Smokers with Rheumatoid Arthritis Who Did Not Respond to Tumor Necrosis Factor Inhibitors Were Treated Successfully with an Anti-Interleukin-6 Receptor Anti... by Yasuo Iwata

“…She was treated with adalimumab due to high disease activity but showed no response over the course of 1.5 years. …”
Get full text